Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

dermal absorption in vivo
Type of information:
migrated information: read-across based on grouping of substances (category approach)
Adequacy of study:
key study
Study period:
31.10.1978 to 03.11.1978
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: The study was well documented and meets generally accepted scientific principles, but was not conducted in compliance with GLP.

Data source

Reference Type:
study report
Report date:

Materials and methods

Test guideline
no guideline followed
Principles of method if other than guideline:
To provide preliminary information about the absorption, distribution and excretion of a compound after its administration to animals.
GLP compliance:

Test material

Constituent 1
Reference substance name:
[[(phosphonomethyl)imino]bis[ethane-2,1-diylnitrilobis(methylene)]]tetrakisphosphonic acid
EC Number:
EC Name:
[[(phosphonomethyl)imino]bis[ethane-2,1-diylnitrilobis(methylene)]]tetrakisphosphonic acid
Cas Number:
[(bis{2-[bis(phosphonomethyl)amino]ethyl}amino)methyl]phosphonic acid
Constituent 2
Reference substance name:
[[(phosphonomethyl)imino]bis[ethane-2,1-diylnitrilobis(methylene)]]tetraki sphosphonic acid (neutralised)
[[(phosphonomethyl)imino]bis[ethane-2,1-diylnitrilobis(methylene)]]tetraki sphosphonic acid (neutralised)
Details on test material:
- Name of test material (as cited in study report): Dequest 2060, neutralised to pH 7.0 with sodium hydroxide.
- Substance type: Phosphonic acid
- Physical state: Slightly yellow liquid
- Radiochemical purity (if radiolabelling): 98% (according to a letter dated 19th Sept 1978 from D.B. Hines to G. Hassins)
- Specific activity (if radiolabelling): 8 microCi/mg (according to a letter dated 19th Sept 1978 from D.B. Hines to G. Hassins)
- Locations of the label (if radiolabelling): C
- Expiration date of radiochemical substance (if radiolabelling): None noted
- Stability under test conditions: No data
- Storage condition of test material: No special precautions noted

Test animals

Details on test animals or test system and environmental conditions:
- Source: Charles River
- Age at study initiation: No data
- Weight at study initiation: 175 to 225 g
- Fasting period before study: yes, overnight and four hours after dosing
- Housing: Metabolism cages
- Individual metabolism cages: yes
- Diet (e.g. ad libitum): Ad libitum
- Water (e.g. ad libitum): No data
- Acclimation period: At least four days

- Temperature (°C): No data
- Humidity (%): No data
- Air changes (per hr): No data
- Photoperiod (hrs dark / hrs light): No data

IN-LIFE DATES: 31.10.1978 to 03.11.1978

Administration / exposure

Type of coverage:
Duration of exposure:
72 hours
- Concentration: 6.1 mg/ml
- Dose volume: 0.1 ml, which contained 2.31 microCi.
- Rationale for dose selection: None given
No. of animals per group:
Three male animals in total
Control animals:
Details on study design:
- Method for preparation of dose suspensions: No data
- Method of storage: No data

APPLICATION OF DOSE: Using Eastman 910 adhesive, a contoured glass ring was glued to the middle of the back of each animal. The ring was 3.6 cm diameter.

- Preparation of test site: Shaved
- Area of exposure: back
- % coverage: No data
- Time intervals for shavings or clipplings: No data

SITE PROTECTION / USE OF RESTRAINERS FOR PREVENTING INGESTION: yes: A porous glass disk was fitted over the skin inside the glass ring. This permited air circulation over the test site, but prevented loss of the test substance by flaking or ingestion.

- Removal of protecting device: After 72 hours
- Washing procedures and type of cleansing agent: No

For 72 hours after dosing the animals were housed in metabolism cages designed to seperate urine, feces and expired CO2. The rats were fitted with fecal cups. Accumulated urine and feces was collected at 24, 48 and 72 hours after application of the test substance. CO2 was collected from the rats at 8 hour intervals for 72 hours (3 samples/day/rat).

- Collection of blood: Blood samples taken at terminal sacrifice at 72 hours.
- Collection of urine and faeces: metabolism cages and fecal cups.
- Collection of expired air: metabolism cages
- Terminal procedure: Ether
- Analysis of organs: All organs and tissues removed for analysis.

- Storage procedure: Samples frozen until analysis.
- Preparation details: Organs and tissues rinsed with water and blotted with paper towel. Fat or connective tissue from the organs removed and placed in sample jars. Organs that have internal cavities (heart, gall and urinary bladders) cut open and rinsed with water. If the urinary bladder contained urine, this urine was rinsed into the urine 48-72 hour collection. Skin samples were taken from the back of the animals. Bone samples were taken from the femur after the bone marrow had been removed. Muscle samples were taken from the hind limb. Adipose tissue samples were taken from the area of the psoas muscle. Carcasses were then frozen with dry ice before grinding in a Wiley mill.

- Method type(s) for identification: Liquid scintillation counting
- Liquid scintillation counting results (cpm) converted to dpm as follows: No details
- Validation of analytical procedure: No details
- Limits of detection and quantification: No details

Results and discussion

Signs and symptoms of toxicity:
no effects
Dermal irritation:
no effects
Absorption in different matrices:
- Non-occlusive cover + enclosure rinse: None reported
- Skin wash: None reported
- SKin adjacent to test site: 0.007 ± 0.002 (mean and SD)
- Skin test site: 89 ± 2% (mean and SD)
- Blood: 0.01 ± 0.01µg/g (mean and SD)
- Carcass: 0.5 ± 0.5% (mean and SD)
- Urine: 0.02 to 2% (mean 0.8%)
- Cage wash + cage wipe: 0.1 ±0.1 (mean and SD)
- Faeces: <=0.01%
- Expired air (if applicable): None reported
- Serial non-detects in excreta at termination: No

- Liver: none detected
- Kidneys: 0.01 ± 0.01% (mean SD)
- Gonads: none detected
- Plasma: none detected
- Muscle: 0.01 ±0.01 µg/g
Total recovery:
- Total recovery: 90%
- Recovery of applied dose acceptable: Accepted as low, but reasonable
- Results adjusted for incomplete recovery of the applied dose: Apparently not
- Limit of detection (LOD): No details
- Quantification of values below LOD or LOQ: No details
Percutaneous absorption
0.1 ml
< 1 %
Remarks on result:
other: 72 hours
Conversion factor human vs. animal skin:

Any other information on results incl. tables

Table 1 Average excretion (% of dose ± SD)

  0 -24 h  24 -48 h  48 -72 h  Total 
Urine  0.7 ± 0.6   0.02  ± 0.01  0.01 ±0.01  0.8  ± 0.7
Feces   0.003  ± 0.003  None detected  None detected  0.0 ± 0.0

Total recovery: 90 ± 3%

Applicant's summary and conclusion

In a dermal metabolism study that predated GLP (reliability score 2) less than 1% of a dermally applied dose (0.1 ml) of neutralised DTPMP was absorbed over a 72 hour exposure period. Most (89 %) of the applied dose was recovered from test site. Total recovery was 90%.